Finelli A - Search Results

1

Active surveillance in patients with a PSA >10 ng/mL.

Toren P, Wong LM, Timilshina N, Alibhai S, Trachtenberg J, Fleshner N, Finelli A. Toren P, et al. Among authors: finelli a. Can Urol Assoc J. 2014 Sep;8(9-10):E702-7. doi: 10.5489/cuaj.2121. Can Urol Assoc J. 2014. PMID: 25408810 Free PMC article.

2

Evidence for a biopsy derived grade artifact among larger prostate glands.

Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE. Kulkarni GS, et al. Among authors: finelli a. J Urol. 2006 Feb;175(2):505-9. doi: 10.1016/S0022-5347(05)00236-3. J Urol. 2006. PMID: 16406982

3

Surgical wait times for patients with urological cancers: a survey of Canadian surgeons.

Fleshner N, Dranitsaris G, Finelli A, Tsihlias J, Bell D, Gleave M; Canadian surgical wait times (SWAT) initiative. Fleshner N, et al. Among authors: finelli a. Can J Urol. 2006 Jun;13 Suppl 3:3-13. Can J Urol. 2006. PMID: 16818006

4

Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature.

Saad F, Finelli A, Dranitsaris G, Goldenberg L, Bagnell S, Gleave M, Fleshner N; Canadian surgical wait times (SWAT) initiative. Saad F, et al. Among authors: finelli a. Can J Urol. 2006 Jun;13 Suppl 3:16-24. Can J Urol. 2006. PMID: 16818008 Review.

5

Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.

Kulkarni GS, Lockwood G, Evans A, Toi A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE. Kulkarni GS, et al. Among authors: finelli a. Cancer. 2007 Jun 15;109(12):2432-8. doi: 10.1002/cncr.22712. Cancer. 2007. PMID: 17497649 Free article.

6

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.

Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R; REDEEM Study Group. Fleshner N, et al. Among authors: finelli a. Contemp Clin Trials. 2007 Nov;28(6):763-9. doi: 10.1016/j.cct.2007.05.006. Epub 2007 May 29. Contemp Clin Trials. 2007. PMID: 17573244

7

Optimal management of high-risk T1G3 bladder cancer: a decision analysis.

Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM. Kulkarni GS, et al. Among authors: finelli a. PLoS Med. 2007 Sep;4(9):e284. doi: 10.1371/journal.pmed.0040284. PLoS Med. 2007. PMID: 17896857 Free PMC article.

8

Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection.

Al-Ghamdi AM, Lockwood G, Toi A, Kulkarni GS, Evans A, Finelli A, Zlotta AR, Fleshner N. Al-Ghamdi AM, et al. Among authors: finelli a. J Urol. 2008 Apr;179(4):1332-4. doi: 10.1016/j.juro.2007.11.067. Epub 2008 Mar 4. J Urol. 2008. PMID: 18289588

9

Effect of healthcare provider characteristics on nodal yield at radical cystectomy.

Kulkarni GS, Finelli A, Lockwood G, Saravanan A, Evans A, Jewett MA, Trachtenberg J, Robinette M, Fleshner NE. Kulkarni GS, et al. Among authors: finelli a. Urology. 2008 Jul;72(1):128-32. doi: 10.1016/j.urology.2008.03.005. Epub 2008 May 2. Urology. 2008. PMID: 18455773

10

The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.

Musquera M, Fleshner NE, Finelli A, Zlotta AR. Musquera M, et al. Among authors: finelli a. Expert Rev Anticancer Ther. 2008 Jul;8(7):1073-9. doi: 10.1586/14737140.8.7.1073. Expert Rev Anticancer Ther. 2008. PMID: 18588452 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

507 results

Search Page

Filters